AG
ARQT icon

Algert Global’s Arcutis Biotherapeutics ARQT Stock Holding History

Algert Global’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$865K Sell
36,720
-49,540
-57% -$1.26M 0.01% 886
2025
Q4 		$2.5M Sell
86,260
-143,132
-62% -$3.66M 0.04% 652
2025
Q3 		$4.32M Buy
229,392
+130,637
+132% +$2.06M 0.07% 451
2025
Q2 		$1.39M Sell
98,755
-22,125
-18% -$310K 0.03% 735
2025
Q1 		$1.89M Buy
120,880
+40,090
+50% +$565K 0.05% 617
2024
Q4 		$1.13M Buy
80,790
+8,310
+11% +$91K 0.03% 751
2024
Q3 		$674K Buy
72,480
+62,065
+596% +$612K 0.02% 838
2024
Q2 		$97K Buy
+10,415
New +$94.2K ﹤0.01% 1393
2022
Q4 		– Sell
-22,126
Closed -$423K – 1128
2022
Q3 		$423K Buy
+22,126
New +$501K 0.03% 856

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return